论文部分内容阅读
钙拮抗剂阻断细胞膜钙离子通道,使细胞内Ca~(2+)浓度降低,从而使血管扩张、血压下降,临床上已列为一线抗高血压药物。然而,近十余年来的临床流行病学资料表明,钙拮抗剂在治疗高血压病的同时,也具有抗动脉粥样硬化作用。在不同的动物实验及最近应用于人体的研究证实,钙拮抗剂的确能使动脉粥样硬化(AS)病变减小甚或完全消退。目前这一作用已基本得到肯定,至于详细机制还不十分清楚,医学家们已经进行了广泛探讨和研究。本文就钙拮抗剂治疗AS作用机理的研究现状及概况作一报道。
Calcium antagonists block the cell membrane calcium channels, Ca2 + intracellular concentration decreased, so that vasodilation, decreased blood pressure, clinically as a front-line antihypertensive drugs. However, clinical epidemiological data in the past ten years indicate that calcium antagonists also have anti-atherosclerotic effects in the treatment of hypertension. Studies in various animal experiments and more recently in humans confirm that calcium antagonists do reduce or even completely diminish atherosclerotic (AS) lesions. At present, this role has basically been affirmed. As for the detailed mechanism is not yet fully understood, medical scientists have conducted extensive discussions and research. This article on the role of calcium antagonists in the treatment of AS research status and overview for a report.